Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
CEX Solutions is a vertical SaaS/enterprise software platform for commercial operations at global pharmaceutical companies. It is operated by Binovate Labs SRL in Bucharest, Romania. The official website emphasizes that this is not a generic SaaS product repurposed for pharma, but a platform built around pharmaceutical commercial workflows, covering core processes such as sales incentives, sales targets, and omnichannel customer touchpoint planning. It is already running in Europe and MENA, with global deployment on AWS.
The platform has three main modules: Incentives Management, Omnichannel CX Planning, and Sales Targets Setting. It brings sales rep incentives, HCP touchpoint journeys, target forecasting, and approvals into a unified workflow, with visualization and audit trails across global, regional, and local levels. Its integration capabilities are strong, covering Veeva CRM, Salesforce Health Cloud, Microsoft Dynamics 365, Snowflake, Databricks, Redshift, Synapse, BigQuery, Power BI, Tableau, Qlik, Looker, as well as pharmaceutical data sources such as IQVIA. On the identity side, it supports SAML, OIDC, SCIM, and providers such as Okta and Microsoft Entra ID.
The official website does not disclose plans, pricing, payment methods, or whether fees are based on users, modules, regions, or projects. It only offers demo bookings. Deployment is a key strength: the platform can be fully managed by the vendor, or installed in the customer’s own AWS account as an internal cloud environment, with the AWS region selected during the contract stage. For compliance, it uses GDPR-native as its privacy baseline, with local frameworks added for MENA, HIPAA-aware positioning for the Americas, and PIPL/MLPS-aware positioning for mainland China. The DPA, subprocessors, and architecture summary are available upon request.
Its developer capabilities are described in relatively complete terms: all customer-visible functionality can be accessed via APIs, with versioned REST APIs, webhooks, OAuth 2.0, service accounts, bulk import/export, OpenAPI 3, CLI, audit logs, and at least 12 months of support for deprecated versions. However, the full API documentation, TypeScript/Python clients, and some materials are only available to customers or qualified partners under NDA.
Its strengths include deep pharma-industry fit, flexible global AWS deployment, strong compliance awareness, a complete integration/API framework, and customer references such as AstraZeneca. The downsides are that pricing is entirely opaque, procurement and evaluation are enterprise-oriented, and public information is limited on granular permissions, implementation timelines, SLA metrics, and live mainland China deployments. It is best suited for multinational pharmaceutical companies, regional commercial operations centers, and teams managing sales incentives and omnichannel operations. It is less suitable for smaller organizations with limited budgets or simple workflows.
The official website says the platform can be deployed in mainland China according to PIPL/MLPS requirements, but it does not state whether the website is directly accessible from China, whether local payment is supported, or whether it already has production environments in China. As a result, China accessibility should be considered unknown. If an enterprise already has an existing ecosystem, alternatives to compare include Veeva Commercial Cloud, Salesforce Health Cloud, IQVIA-related commercial solutions, or Microsoft Dynamics 365 with industry-specific implementation services.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on cex-solutions.com official site.
cex-solutions.com is an Europe SaaS provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach cex-solutions.com directly.